The Latest
Launch HN: ProvenMetal (YC S26) Delivers Circuit Boards In Days Instead Of Weeks

Launch HN: ProvenMetal (YC S26) Delivers Circuit Boards In Days Instead Of Weeks

ProvenMetal, a YC S26 startup, now delivers assembled circuit boards in days instead of weeks, streamlining hardware prototyping and manufacturing.
Herdr Is Joining Y Combinator. The Runtime Stays Open

Herdr Is Joining Y Combinator. The Runtime Stays Open

Herdr has announced its participation in Y Combinator, with its runtime continuing to operate openly. This move signals growth and strategic positioning.
AMD Acquires Taalas To Boost Inference Performance By Etching Models In Silicon

AMD Acquires Taalas To Boost Inference Performance By Etching Models In Silicon

AMD has acquired Taalas to improve AI inference by etching models directly into silicon, aiming to boost efficiency and performance in AI workloads.
Will Elon Musk Post 200-219 Tweets From July 31 To August 7, 2026?

Will Elon Musk Post 200-219 Tweets From July 31 To August 7, 2026?

Speculation surrounds Elon Musk’s potential to post 200-219 tweets during late July to early August 2026, with market data indicating a 40% probability.
hoverboard with seat stability

You Won’t Believe How Hoverboard With Seat Can Secure Your Future

Discover how a hoverboard with a seat can revolutionize your mobility and secure your future—find out what makes it so essential.
crypto asset risk strategies

Risk Management Strategies for Volatile Crypto Assets

Discover essential risk management strategies for volatile crypto assets that can help you protect your investments and navigate unpredictable markets effectively.

Personal Finance & Investing Essentials 2026

Welcome to your ultimate guide to personal finance and investing in 2026.…
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER

ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER

ArcPoint announced a cease trade order due to failure to file financial documents, raising concerns among investors and regulators.
Galibra Neuroscience Receives FDA Orphan Drug And Rare Pediatric Disease Designations For SSADH Deficiency Gene Therapy

Galibra Neuroscience Receives FDA Orphan Drug And Rare Pediatric Disease Designations For SSADH Deficiency Gene Therapy

Galibra Neuroscience receives FDA orphan drug and rare pediatric disease designations for its SSADH deficiency gene therapy, advancing its development pipeline.
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging

AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging

Insilico Medicine announces ISM9077 as a potential first-in-class Y Inhibitor for ocular, inflammatory, and aging diseases, advancing AI-driven drug discovery.